Novel Minimally Invasive Endobronchial Approach for Lung Cancer Ablation

Information

  • Research Project
  • 9774511
  • ApplicationId
    9774511
  • Core Project Number
    R43CA239829
  • Full Project Number
    1R43CA239829-01
  • Serial Number
    239829
  • FOA Number
    PA-18-574
  • Sub Project Id
  • Project Start Date
    4/1/2019 - 5 years ago
  • Project End Date
    8/31/2019 - 5 years ago
  • Program Officer Name
    CANARIA, CHRISTIE A
  • Budget Start Date
    4/1/2019 - 5 years ago
  • Budget End Date
    8/31/2019 - 5 years ago
  • Fiscal Year
    2019
  • Support Year
    01
  • Suffix
  • Award Notice Date
    3/26/2019 - 5 years ago
Organizations

Novel Minimally Invasive Endobronchial Approach for Lung Cancer Ablation

PROJECT SUMMARY: Lung cancer is one of the most aggressive and common malignancies world-wide. While surgical resection remains the best chance of cure, only 20% of patients are eligible for surgery. The remaining patients are managed with combinations of radiotherapy and chemotherapy and more recently with less invasive stereotactic radiotherapy and percutaneous thermal ablation. Percutaneous radio-frequency ablation (RFA) or microwave ablation are cost-effective treatment options for unresectable tumors. This minimally invasive approach, though effective for treatment of some stage 1 and 2 non-small cell lung carcinomas either alone or in combination with other therapies, suffer in terms of their ability to create thermal destruction of the tumors with sufficient margin without risking serious adverse events like pneumothorax and collateral injury. The goal of this proposal is to refine the design of a full-length, endobronchial RFA system that is compatible with the working channel of a bronchoscope and can achieve thermal ablation of peripheral nodules 2-3 cm in diameter with minimal risk of pneumothorax. Our innovative approach overcomes past attempts of using RFA to make large lesions without crossing the airway by combining, in a single device, air aspiration and irrigation flow to increase lesion together with a custom RF generator algorithm. Our device is designed to be compatible with contemporary navigation systems and could be used in conjunction with currently available tools for lung tumor biopsy or imaging (e.g., radial EBUS). This project will be completed in several sequential stages. For this Phase I SBIR we will demonstrate proof of technical concept that our innovative approach to RFA with a device completely in the airway can make large lesions in preclinical models without causing acute pneumothorax despite close proximity to the pleura. Successful completion of the specific aims will lead to the development of a clinical-grade device that can be validated and verified with modern navigation tools to safely and effectively ablate tumor phantoms planned for Phase II of the project.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    224929
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:224929\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CORIDEA, LLC
  • Organization Department
  • Organization DUNS
    079248612
  • Organization City
    NEW YORK
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    100186404
  • Organization District
    UNITED STATES